You are here: Home » Current Affairs » Coronavirus » News
To bolster security, Britain joins Indian Ocean monitoring hub in Gurgaon
Covid-19 vaccine shortages hit global supply initiative, halting rollouts
Business Standard

Bharat Biotech's Covaxin shows over 77% efficacy in phase 3 trials

The vaccine has shown an efficacy rate of 93 per cent against severe disease and 60 per cent against asymptomatic Covid-19

Topics
Bharat Biotech | Coronavirus Vaccine | Vaccination

Sohini Das  |  Mumbai 



Covaxin, bharat biotech, coronavirus vaccine
Now that the data from phase 3 trials has been reviewed by the drug regulator of the country of origin, the firm can present it before the World Health Organization

Bharat Biotech’s Covaxin, India’s first indigenous against Covid-19, has shown 77.6 per cent efficacy in the final analysis of phase 3 clinical trials, according to sources in the expert panel that reviewed the data.

TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.

SUBSCRIBE TO INSIGHTS

What you get on Business Standard Premium?

  • icon Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • icon Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • icon Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
  • icon Pick your 5 favourite companies, get a daily email with all news updates on them.
  • icon 26 years of website archives.
  • icon Preferential invites to Business Standard events.

OR


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

Download the Business Standard App for latest Business News and Market News .

First Published: Wed, June 23 2021. 00:42 IST

RECOMMENDED FOR YOU